We evaluated isovolumic hemodilution with hydroxyethyl starch 200/0 .5 in a rat model of focal cerebral ischemia. This compound avoids the unfavorable viscosity and erythrocyte aggregation abnormalities of low molecular weight dextran during administration over a period of several days.
H emodilution has been advocated for stroke treatment 1 because cerebral blood flow (CBF) in normal brain increases with decreasing hematocrit." In ischemic regions, CBF also increases as hematocrit falls. 4 Hemodilution is felt to be particularly effective in ischemia due to viscosity reduction in the microcirculation with its low shear rate.
Unfortunately, most clinical trials of hemodilution have produced negative results, 5 " 7 whereas experimental studies using low molecular weight dextran (LMWD) 8 and LMWD in combination with nimodipine 9 have been encouraging. The lack of success in clinical trials may in part be due to relatively delayed treatment after stroke onset, 10 insufficient reduction of hematocrit after hemodilution treatment, and the presence of hypovolemia. 11 This conjecture is supported by the results of a study that used a lower target hematocrit ' 13 More recently, the complex polymer hydroxyethyl starch (HES) 200/0.5 has been used in stroke therapy, because it decreases thrombocyte and erythrocyte aggregation over administration periods of 2-3 days, in contrast to LMWD.
14 LMWD is associated with increased viscosity with long-term administration lasting for more than 3 days. 15 In addition, HES does not exacerbate cerebral edema in cerebral ischemia. 16 This study evaluates the use of 10% HES 200/0.5 with isovolumic hemodilution as stroke therapy in a rat model of focal embolic cerebral ischemia.
Materials and Methods
Twenty-four male Sprague-Dawley rats weighing 305 ±5 g (mean±SEM) were orally intubated and mechanically ventilated (model 683, Harvard Apparatus, South Natick, Mass.) with 0.5-1% halothane, 70% N 2 O, and 30% O 2 . Body temperature was maintained at 37°C with a servo-controlled heating lamp and a rectal thermistor (YSI 74, Yellow Springs Instrument Co., Yellow Springs, Ohio). Femoral arteries and veins on both sides were cannulated with polyethylene tubing. The left common carotid artery was accessed by a midline neck incision, and the left pterygopalatine artery was cauterized. The left external carotid artery was cannulated retrogradely. For electroencephalographic (EEG) recording over the middle cerebral artery (MCA) territory, five stainless-steel screws were placed in the skull and embedded in dental acrylic (Lang Dental, Chicago). The reference electrode was placed 11 mm rostral to bregma on the midline, and bilateral, bipolar electrodes were placed 4 and 9 mm lateral to bregma. Total surgery time averaged 180 minutes.
While the animals were under anesthesia, mean arterial blood pressure and end-tidal CO 2 were continuously monitored with a pressure transducer (MP-15D, Micron Instruments, Los Angeles) and infrared CO 2 detector (model 223, Puritan-Bennet, Boston), respectively, and were recorded on a polygraph (RS-3800, Gould Instruments, Cleveland, Ohio). Arterial blood gases (Pacch, Pac^) and pH were determined (ABL-3, Radiometer, Copenhagen), and hematocrit was measured with microhematocrit capillary tubes after centrifugation. Total plasma volume was determined with dye dilution after intravenous injection of a 0.05-ml bolus of Evans blue (7.5 mg/ml in saline, J.T. Baker Chemical Co., Phillipsburg, N.J.). Dye concentration was determined from samples withdrawn from the ipsilateral femoral artery 5 minutes later by spectrophotometric analysis (wavelength, 605 nm). Total blood volume per body weight was calculated from the plasma volume, hematocrit, and body weight. 17 Plasma glucose level was determined with a membrane-bound glucose oxidase analyzer from previously frozen arterial plasma samples (YSI model 27, Yellow Springs Instrument Co., Yellow Springs, Ohio). All physiological variables were determined with rats under anesthesia before embolization (t=0) and at 1.5 and 24 hours. Bipolar EEG over both MCA territories was recorded just before embolization (or sham embolization with only saline) and at 10 minutes and 24 hours after embolization and was immediately processed using Fourier frequency analysis with a digitizing system (Rhythm, Stellate Systems, Westmount, Canada). The postembolization EEG ratio was calculated as 100 • [(Apo,,^,, • A prcconlr ,)/ (Apn^ • Apccoou,)-!], where the A values represent the amplitude from 1 to 21 Hz before and after embolization from the contralateral and ipsilateral sides to the embolus. An EEG ratio of 0% indicates that there has been no change, whereas an EEG ratio of -90% indicates a 90% reduction from the preembolization EEG amplitude. This formulation controls for both side-to-side and time variations that are independent from the effects of embolization.
Animals were divided into three study groups: treatment (TRT), control (CNTL), and sham. Animals were randomly assigned either to the sham group or for embolization. The EEG ratio was applied as an inclusion criteria to ensure that embolized animals had an amplitude reduction less than -4 5 % , indicating a large ischemic insult, before further randomization to either the CNTL or TRT groups. One sham animal was excluded because of an EEG ratio of -6 3 % , possibly due to accidental infusion of an air embolus (animal No. 13, Table 1 ). A silicone cylinder (0.8-1.0x0.3 mm) was infused with 0.8 ml of 0.9% saline solution into the left external carotid artery cannula, 18 while the ipsilateral common carotid artery was momentarily occluded with an aneurysm clip. The protocol for sham animals was analogous to that of the CNTL and TRT groups, except that saline without a silicone cylinder was injected into the external carotid artery cannula. Thirty minutes later, TRT animals were infused with 11 ml/kg of HES (HAES-steril 10%, Fresenius AG, Bad Homburg, FRG) over 1 hour, and a total blood volume per body weight of 7.1 ml/kg was withdrawn in four increments at 15-minute intervals. The CNTL and sham animals received an equal volume of saline with no blood withdrawal. The animals were then allowed to recover from anesthesia with free access to food and water.
Animals were reanesthetized 24 hours later with the same anesthetic regimen. CBF was measured using the tissue equilibration technique. 19 During a 45-second period, 100 ^,Ci/kg of [ 14 C]iodoantipyrine mixed with 0.8 ml saline solution was continuously infused intravenously. Concurrently, 10-15 arterial blood samples were obtained in 20-jil capillary tubes, spotted on a filter paper strip, dried, and counted using liquid scintillation. At the end of the 45 seconds, the animals were decapitated, the brain was removed, and the silicone cylinder was visually located. If the silicone cylinder lodged in the anterior cerebral artery or internal carotid artery or was not found, the animal was excluded from the treatment and control groups (see Table 1 ). Ten to 12 brain slices (2 mm thick) were obtained in a matrix device.
Alternate 2-mm slices were incubated with 2,3,5-triphenyltetrazolium chloride at 40°C for 15 minutes. Photographic transparencies from both the rostral and caudal faces of these slices were evaluated with an image analyzer 20 for total slice and infarct area. Lack of tetrazolium staining (white), as opposed to normal tissue (red), indicated infarcted area 21 (see Figure 1 ). Infarct volume percent, defined as the percent of total brain volume that was infarcted, was calculated from at least eight sections 22 using the algorithm for the volume of a frustum of a cone. 9 The remaining alternate slices were immediately frozen in chlorodifluoromethane (-44°C) and later sectioned at 20 /im in a cryostat (-12°C). Every 10th section and eight precalibrated [ u C]methylmethacrylate standards were exposed to x-ray film (SB5, Eastman Kodak Co., San Diego, Calif.) for 4 days. Autoradiograms of sections from each rostral and caudal face of each 2-mm slice were analyzed for total and ischemic areas, defined as the area with a CBF less than 25 ml/min/100 g, 23 using the image analyzer 20 ( Figure 1 ). Ischemic volume percent was calculated from at least eight sections 22 using the algorithm for the volume of a frustum of a cone. 9 Three consecutive autoradiographic sections from each animal, centered on the largest ischemic area, were selected for measurement of CBF in five regions of interest: 1) left ischemic cortex, with CBF less than 25 ml/min/100 g (except in three TRT animals that did not have an ischemic core with CBF values less than this level); 2) left anterior cerebral artery territory; 3) right anterior cerebral artery territory; 4) right normal cortex contralateral to the ischemic area; and 5) right white matter. CBF values determined from the three sections for each region of interest were averaged for each animal, and these values provided the mean and SEM for that region of interest for each group. SHAM  CNTL  CNTL  CNTL  SHAM  SHAM  TRT  CNTL  TRT  SHAM  CNTL  CNTL  SHAM  CNTL  CNTL  CNTL  CNTL  TRT  TRT  CNTL  TRT  CNTL  CNTL  TRT  24  16  14  15 EEG, electroencephalogram; ISV, ischemic volume; IFV, infarct volume; NE, no emboli (sham); MCA, middle cerebral artery, CNTL, control; PCA, posterior cerebral artery; ACA, anterior cerebral artery; TRT, treatment group; SIM, segment between internal carotid and middle cerebral arteries; NF, not found; ICA, internal carotid artery.
'These animals satisfy the inclusion criteria for treatment evaluation: EEG ratio <-45% and cylinder in MCA or PCA.
tThis animal died during the cerebral blood flow study, but its infarct volume is used for treatment evaluation.
Ischemic and infarct volumes were used for the evaluation of the effect of hemodilution in five CNTL, five TRT, and four sham animals, although the ischemic volume was not obtained in one CNTL animal that died during the CBF study (animal No. 2, Table 1 and Table  2 ). Ten animals were excluded in this analysis because they did not satisfy the inclusion criteria for treatment evaluation ( Table 1 ). The relation between ischemic and infarct volumes was assessed by linear regression using 15 animals, some of which did not meet the inclusion criteria for treatment evaluation but did have both ischemic and infarct volumes.
The mean and SEM were used for descriptive statistics. Analysis of variance was performed to determine treatment differences, effects of time after embolization, and interaction of treatment and time effects for physiological data. Specifically, linear models were used with treatment defined as a between-animal factor and either time or region as within-animal factors. Univariate and multivariate techniques were applied as dictated, by the data. Univariate analysis was used only if differences between all pairs of repeated measurements (CBF over region and hematocnt over time) were equally variable across treatment groups. Main effect differences for treatment and time could not be used from the full model for CBF and hematocrit because of the highly significant interaction between treatment and time. Therefore, a one-way analysis of variance was performed at each time point to determine treatment group differences. Within-group comparisons were made using univariate and multivariate repeated measures techniques. Specific comparisons between groups were made using t tests, and within-group specific comparisons were made using paired t tests. A logarithmic transformation was used for the CBF values of the ischemic cortex. Significance levels were adjusted using the Bonferroni method. A linear regression model and the coefficient of determination were used to describe the relation between ischemic volume percent and infarct volume percent. 24 A t test was used to determine whether the slope differed from 1. Statistical analyses were performed with the SAS system. 25 
Results
There are no statistically significant differences in Pach, mean arterial blood pressure, or total blood volume per body weight within or among groups, as shown in Table 3 . Both Pacx^ and pH showed small but significant differences over time that are not relevant to the outcome. Plasma glucose values are significantly Figure 2 both before and 24 hours after embolization. TRT animals show a statistically significant improvement in their EEG ratios from 10 minutes to 24 hours (p<0.05). The EEG ratios for the CNTL group at 10 minutes are similar to the TRT group and did not recover at 24 hours but remain at this depressed level. EEG ratios for the sham group did not differ from zero. For all embolized animals in Table 1 (n=18, excluding the one in which the cylinder was not found), 61% (n=ll) of the single silicone cylinders were found in the MCA, 11% (n=2) in the posterior cerebral artery, 17% (n=3) in the anterior cerebral artery, 5.6% (/i = l) in the internal carotid artery, and 5.6% (n = l) in the segment of the Circle of Willis between the internal ISV, ischemic volume; IFV, infarct volume; TRT, treatment; CNTL, control.
•These animals satisfy the inclusion criteria for treatment evaluation; electroencephalographic ratio < -45% and cylinder in middle or posterior cerebral artery.
tCerebral blood flow and ISV are reported in only four animals because one animal died during the cerebral blood flow study, but its infarct volume is used.
carotid artery and MCA. In the embolized animals that were used for treatment evaluation, 90% of cylinders lodged in the MCA.
The TRT group shows a significant reduction in hematocrit (see Figure 3 ) from 46±1% to 35±2% (/><0.01) 1.5 hours after embolization (1 hour after the start of HES infusion) and to 32±4% at 24 hours (p<0.05). In the CNTL group, there is a small decrease of hematocrit from baseline: 47±1%, 45±0.4%, and 45±0.4% at baseline, 1.5 hours, and 24 hours, respectively. The hematocrit of the CNTL group drops only 3%, significantly different from the decrease of the TRT group (p<0.05). In the sham animals, hematocrit drops from 46±1% to 39±1% at 24 hours (p<0.05). The hematocrit of the TRT animals is lower than the sham and CNTL at 1.5 hours (p<0.01, p<0.01) and the CNTL at 24 hours (/><0.05).
CBF was measured 1 day after both embolization and hemodilution or control procedures (see Table 4 , Figure  1 ). Right normal cortical CBF values are within the normal range of 115-185 ml/min/100 g in all the groups. In the ischemic cortex of the embolized groups, TRT and CNTL, CBF is reduced by 71% (100-[TRT/sham • 100]; p<0.01) and 94% (100-[CNTL/sham-100]; p<0.01) from the sham value, respectively. These percent reductions of CBF in the ischemic cortex of the TRT and CNTL groups do not differ, even though CBF values for three of the TRT animals are higher than 25 ml/min/100 g in this region. The mean flow for the white matter, in all groups, is 53±5 ml/min/100 g.
Linear regression between the ischemic volume percent (ISV) and infarct volume percent (IFV) shows a strong linear association, in animals included (« = 15) in the correlation analysis (see Table 1 ), between the two methods of evaluating the affected volume (see Figure  4 ). The coefficient of determination is 0.87 and the regression equation is ISV=0.87 • IFV+0.24. The slope of 0.87 is not significantly different from 1. The correspondence between the ischemic area and infarct, as determined by tetrazolium staining, is also evident from Figure 1 , which shows a CBF autoradiogram and an adjacent tetrazolium-stained section. The infarct and ischemic volumes of the TRT group are not statistically different from those of the sham animals (see Figure 5 ), whereas the infarct volumes of the CNTL group are statistically different from both the sham and TRT group values. The ischemic volume percent is 1.67±0.55% in the TRT group, 6.40±2.72% in the CNTL group, and 0.68±0.20% in the sham group (p<0.01 for CNTL versus SHAM or TRT). The infarct volume percent is 0.86 ±0.42% in the TRT group, 8.05±1.48% in the CNTL group, and 0.42±0.17% in the sham group (p<0.05 for CNTL versus TRT or SHAM). HES reduced the ischemic volume percent by 74% from the CNTL group and the infarct volume percent by 89% from the CNTL group.
Discussion
The predominant finding of this study is that HES therapy reduced the brain infarct and ischemic volumes to values that are lower than those of the CNTL animals Values are mean±SEM, expressed as milliliters per minute per 100 g. RAC, right anterior cerebral artery territory; LAC, left anterior cerebral artery territory, RNC, normal cortex contralateral to ischemic area; LIC, left ischemic cortex, with cerebral blood flow less than 25 ml/min/100 g; RWM, right white matter, TRT, embolized and treated; CNTL, embolized and not treated; SHAM, not embolized and not treated.
FIGURE 2. Bar graph shows electroencephalographic (EEG) amplitude ratio normalized to the contralateral side andpreembolization period. There is a significant reduction in the treatment (TRT) group (p<0.05), whereas the control (CNTL) group remains near the postembolization value at 24 hours.
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•Significantly different from SHAM (/7<0.01). tSignificanth/ different from CNTL (p<0.05). tCerebral blood flow values are reported in only four animals because one CNTL animal died during the cerebral blood flow study.
and comparable to those of the sham animals. The EEG ratio in TRT animals shows a significant recovery 1 day after stroke that is not observed in CNTL animals. These results are in direct contrast to those of most clinical trials for hemodilution therapy. Our success is most probably based on our choice of hemodilutant (HES), its composition (200/0.5, 10%), and the ultraearly onset of treatment (30 minutes). These results show the potential benefit of this protocol and how it can be applied in the corresponding subset of stroke patients, because our model is a valid representation of clinical embolic stroke.
The silicone cylinder embolization model 18 is a more clinically relevant model than the MCA occlusion technique, because it minimizes tissue damage, avoids craniotomy, and thus maintains a closed skull during stroke. Our model and clinical stroke both suffer from the deleterious effect of raised intracranial pressure due to edema, in contrast to the model that uses direct occlusion of the MCA, which requires craniotomy and disruption of the dura mater, where the intracranial pres- sure increase due to ischemic edema is minimized. In addition, the surgery for the embolization model is less traumatic, less technically demanding, and permits quicker postsurgical recovery because the muscles of mastication are left undisturbed.
Rat stroke models suffer from large variability of infarct volume, 26 complicating the evaluation of stroke agents. Our implementation of this embolic stroke model reduces the variability in infarct size, because only animals with postembolization EEG ratios less than -4 5 % (Table 1) are included in the TRT and CNTL groups. Thus, animals that did not have a stroke, had a small stroke, or had a stroke outside of the sensitive area of the bipolar EEG electrodes are not randomized to either the CNTL or TRT group. Small strokes in the CNTL group would increase the variability in infarct volume, making statistical comparison with the TRT group more difficult. In contrast, small strokes in the TRT group would be confused with successful treatments. The importance of the EEG ratio as a useful parameter for the assessment of initial stroke severity is demonstrated in the TRT group: The 24-hour EEG ratio shows a statistically significant improve- ment, indicating treatment effectiveness by this relatively nonspecific, but noninvasive, measure of brain function (see Figure 2 ). This improvement is not observed in the CNTL group.
The variability of our embolic stroke model is further reduced by two other factors that avoided the possibility of contralateral ischemia: 1) The use of a clamp on the common carotid artery during embolus infusion prevented the single embolus from crossing to the contralateral common carotid artery by retrograde travel down the ipsilateral common carotid artery and through the aorta; and 2) animals in which the cylinder lodged in the anterior cerebral artery emboli were excluded. Because the normal Sprague-Dawley rat has a single anterior cerebral artery that supplies both hemispheres, an embolus in this artery could cause bilateral ischemia. For these reasons, our embolic stroke model does not suffer from the confounding problem of previous large emboli and microembolic stroke models of uncertain embolus location, contralateral and multifocal ischemia, and transient occlusion. 27 -30 As shown in Table 1 for all the embolized animals (n = 18), cylinders lodged most frequently (61%) within the MCA, whereas for the embolized animals that were used for treatment evaluation, 90% were found in the MCA. However, the success of a model of focal cerebral ischemia for determining therapeutic effectiveness depends on the variability of infarct volume, not on the artery that is embolized. The coefficient of variation in cortical infarct volume observed in CNTL animals (41%) is within the range observed by Brint et al 31 of 16-149% in Wistar rats but is greater than that observed by Duverger et al 32 of 33% in the same species. This single embolus model has an acceptable coefficient of variation, because the exclusion criteria of cylinder location and EEG ratio are an integral part of the model.
The threshold of CBF that was chosen to define the ischemic volume, 25 ml/min/100 g, is slightly low, because the slope of the linear regression between infarct and ischemic volumes is 0.87, although it is not significantly different from 1, as shown in Figure 4 . This value of 25 ml/min/100 g is a conservative value from the range of 25-35 given by Tyson et al 23 for the threshold after stroke that determines future cell viability within the first 1-4 hours. The CBF threshold at 24 hours indicates the border between already dead and still viable neurons. Although this threshold is lower than that recently proposed by Jacewicz et al, 33 the ischemic border is steeper in our model, so presumably there would not be a large difference in ischemic volume if the ischemic threshold were raised. Our confidence in the limit of 25 ml/min/100 g for the definition of infarct 24 hours after the ischemic insult is bolstered by the agreement shown in Figure 4 with tetrazolium staining: The coefficient of determination is 0.87.
CBF increases in normal brain during acute hemodilution in animals using plasma 2 or HES 3 and in humans using LMWD. 4 The acute increase in CBF could be due to the direct physical effect of the lowered viscosity of blood or the indirect physiological effect of hypoxia on CBF. The mechanism by which CBF increases in normal brain with acutely lowered hematocrit remains controversial 34 - 35 and is not understood completely. 2 However, there have been few measurements of CBF after hemodilution lasting for 24 hours. Our results indicate that CBF in normal cortex, measured after 24 hours of hemodilution to a hematocrit of 32% in the TRT group, is not elevated. The lack of a significant increase in CBF in normal cortex in the TRT group might reflect the normalization of CBF at 24 hours after HES infusion. A sample size analysis using the most favorable assumptions showed that a total of 95 animals would be needed to detect a significant increase in CBF of the same magnitude with 80% power. With continued administration of the hemodilutant during 24 hours, both Hartmann et al 36 and Adams et al 37 demonstrated increases of CBF. Hartmann et al 36 observed a small 5-10% increase in CBF after 1 day of HES 200/0.5 hemodilution, which decreased the hematocrit from 44% to 39%. 36 With a more substantial decrease of hematocrit from 41% to 33% 25 hours after hypervolemic hemodilution with HES 250/0.7 in elderly stroke patients, Adams et al 37 measured a 60% increase in CBF in both the ischemic and contralateral hemispheres. 37 Stroke therapy with hemodilution is not aimed at normal cortex or at the ischemic core, where oxygen delivery is no longer an issue, but at the border zone surrounding the core where viscosity reduction may be a major factor for increasing flow. In the border zone, hemodilution may increase flow through its effect on viscosity even if the primary mechanism by which it increases CBF in normal tissue is through the physiological response of the cerebral circulation to lowered oxygen-carrying capacity of blood. Viscosity is increased disproportionately at low flow rates. As the shear rate falls, viscosity may increase many times, leading to a further decrease in flow. A vicious cycle might be started that could prevent the ischemic border zone from recovering. 38 If hemodilution reduces viscosity in these low flow areas, this vicious cycle could be broken. Thus, one of the proposed mechanisms by which hemodilution reduces infarct volume at 24 hours is the acute increase in CBF in ischemic and surrounding regions. 3940 The significantly lower ischemic volume in the TRT group at 24 hours implies that HES administration elevated CBF in the ischemic border zone.
Another possible mechanism that relates to viscosity reduction and could apply to the border zone is that HES is known to reduce erythrocyte aggravation.
14 This mechanism would increase CBF in just those regions that are at the most risk and could explain the beneficial effect of HES administration on infarct and ischemic volumes.
The hemodilution protocol used in this study achieves the desired low level of hematocrit within 1.5 hours and maintains it for 24 hours. For clinical use, either the continued administration of HES on a daily basis would be required 14 or a longer lived hemodilutant such as albumin could be used. 11 One possible complication of HES, noted with another formulation of HES (450/0.7) and with higher doses than were used in this study, is its interaction with factor VIII and prolongation of the partial thromboplastin time. 41 Our low HES 200/0.5 dosage caused no bleeding. Isovolumic hemodilution was documented by the consistency of total blood volume/body weight over groups and time. In contrast to the invasive Swan-Ganz monitoring suggested for hypervolemic hemodilution, 7 this isovolumic protocol is relatively easy and safe. Different formulations of HES may not be equally effective for hemodilution. The different formulations of this poh/saccharide are characterized by the average molecular weight (in kilodaltons, e.g., 200), degree of substitution (number of anhydroglucose residues on the polymer chain, e.g., 0.5), and pattern of substitution (which is usually not specified). All three parameters control the degradation of HES to smaller molecules by plasma cr-amylase and subsequent renal excretion of these smaller units.
Theoretical studies have suggested that a hematocrit of 30% is the lower limit below which oxygen delivery is compromised and at which the trade-off between increased CBF and reduced oxygen delivery peaks. 42 -43 Successful laboratory studies have all reduced hematocrit to between 32% and 35% within 1 to 1.5 hours, whereas most clinical trials have reached a hematocrit of 36-40% at 24 hours after stroke onset or entry time. A lower hematocrit could explain the reduction of infarct volume in treated animals, because viscosity reduction potentially improves the microcirculation in still viable, but ischemic, areas. 38 The elapsed time from stroke onset to treatment is crucial for the success of any drug used in clinical trials. 10 Delayed treatment beyond a 2-3-hour "therapeutic window" may mark the difference between reversible and irreversible brain damage. 44 In the Scandinavian study, 5 only 28% of the subjects were entered within 12 hours. In the Italian study, 6 all subjects were entered within 12 hours and 55% within 6 hours. Within 1 hour after LMWD administration, an increase of CBF has been observed in human stroke patients. 4 In animals, an increase of CBF is associated with a reduction in ischemic or infarct volumes with LMWD monotherapy 8 or with LMWD in combination with nimodipine. 9 Our results indicate that HES treatment is effective in greatly reducing brain infarct and ischemic volumes associated with ischemic stroke, as well as improving brain function as expressed in the E E C We suggest that this positive result is due to the low target hematocrit of 32%, a minimum entry time of less than 3 hours, and the use of HES 200/0.5.
Because the pathophysiology of ischemic stroke is a complex, multifactorial process, a therapeutic approach using a "therapeutic cocktail" that includes HES is justified. Hemodilution could play a role in early stroke therapy and at this stage should be evaluated clinically with proper attention to ideal parameters for entry time and target hematocrit. Studies in other species and models are needed to validate these results, to categorize the area saved by this therapeutic agent, and to determine the true clinical benefit of reduction in infarct size.
